Brokers Issue Forecasts for HCA Healthcare, Inc.’s Q4 2020 Earnings (NYSE:HCA)

Samuel Edwards

Published on:

HCA Healthcare, Inc. (NYSE:HCA) – Jefferies Financial Group boosted their Q4 2020 earnings per share estimates for HCA Healthcare in a note issued to investors on Tuesday, October 27th. Jefferies Financial Group analyst B. Tanquilut now expects that the company will earn $3.82 per share for the quarter, up from their previous estimate of $3.49.

HCA Healthcare (NYSE:HCA) last announced its earnings results on Monday, October 26th. The company reported $1.92 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.69 by ($0.77). HCA Healthcare had a net margin of 6.67% and a negative return on equity of 589.47%. The firm had revenue of $13.31 billion for the quarter, compared to the consensus estimate of $12.92 billion. During the same period in the prior year, the business earned $2.23 EPS. The company’s quarterly revenue was up 4.9% compared to the same quarter last year.

Several other equities research analysts also recently commented on HCA. Mizuho upped their target price on HCA Healthcare from $145.00 to $150.00 and gave the company a “buy” rating in a report on Tuesday. Truist upped their target price on HCA Healthcare from $150.00 to $165.00 and gave the company a “buy” rating in a report on Wednesday, September 16th. BMO Capital Markets downgraded HCA Healthcare from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $121.00 to $100.00 in a report on Monday, July 13th. Raymond James upped their target price on HCA Healthcare from $140.00 to $150.00 and gave the company an “outperform” rating in a report on Tuesday. Finally, Barclays increased their price objective on HCA Healthcare from $140.00 to $150.00 and gave the stock an “overweight” rating in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. HCA Healthcare currently has a consensus rating of “Buy” and a consensus target price of $152.10.

Shares of NYSE HCA opened at $123.94 on Thursday. HCA Healthcare has a 12 month low of $58.38 and a 12 month high of $151.97. The company has a market cap of $41.90 billion, a price-to-earnings ratio of 12.78, a P/E/G ratio of 1.20 and a beta of 1.39. The company has a quick ratio of 0.95, a current ratio of 1.09 and a debt-to-equity ratio of 54.19. The business has a fifty day simple moving average of $130.50 and a 200-day simple moving average of $117.55.

Several hedge funds and other institutional investors have recently modified their holdings of HCA. Sanders Capital LLC acquired a new position in shares of HCA Healthcare during the 2nd quarter valued at about $723,683,000. Fort Washington Investment Advisors Inc. OH acquired a new stake in HCA Healthcare in the 2nd quarter valued at approximately $81,520,000. FIL Ltd grew its holdings in HCA Healthcare by 47.5% in the 2nd quarter. FIL Ltd now owns 2,163,384 shares of the company’s stock valued at $209,978,000 after buying an additional 696,740 shares during the last quarter. FMR LLC grew its holdings in HCA Healthcare by 42.3% in the 2nd quarter. FMR LLC now owns 2,148,926 shares of the company’s stock valued at $208,575,000 after buying an additional 638,628 shares during the last quarter. Finally, Nordea Investment Management AB grew its holdings in HCA Healthcare by 122.4% in the 2nd quarter. Nordea Investment Management AB now owns 1,147,616 shares of the company’s stock valued at $107,968,000 after buying an additional 631,592 shares during the last quarter. 68.28% of the stock is currently owned by institutional investors and hedge funds.

In other news, insider A Bruce Moore, Jr. sold 15,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $133.73, for a total transaction of $2,005,950.00. Following the transaction, the insider now owns 88,626 shares of the company’s stock, valued at approximately $11,851,954.98. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP P. Martin Paslick sold 254 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $132.97, for a total value of $33,774.38. Following the transaction, the senior vice president now directly owns 5,442 shares in the company, valued at approximately $723,622.74. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,331 shares of company stock worth $2,183,838. Insiders own 1.80% of the company’s stock.

The company also recently announced a monthly dividend, which will be paid on Thursday, November 12th. Shareholders of record on Friday, October 30th will be given a $0.072 dividend. This represents a $0.86 annualized dividend and a yield of 0.70%. The ex-dividend date is Thursday, October 29th.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, operates as a health care services company in the United States. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.

Read More: The benefits and drawbacks of dollar cost averaging

Earnings History and Estimates for HCA Healthcare (NYSE:HCA)

Receive News & Ratings for HCA Healthcare Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for HCA Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Comment